Foghorn Therapeutics Inc. (FHTX)
NASDAQ: FHTX · Real-Time Price · USD
5.14
+0.16 (3.21%)
Dec 20, 2024, 4:00 PM EST - Market closed
Foghorn Therapeutics Employees
Foghorn Therapeutics had 116 employees as of December 31, 2023. The number of employees decreased by 45 or -27.95% compared to the previous year.
Employees
116
Change (1Y)
-45
Growth (1Y)
-27.95%
Revenue / Employee
$219,957
Profits / Employee
-$786,405
Market Cap
285.75M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 116 | -45 | -27.95% |
| Dec 31, 2022 | 161 | 42 | 35.29% |
| Dec 31, 2021 | 119 | 24 | 25.26% |
| Dec 31, 2020 | 95 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Accolade | 2,400 |
| Canopy Growth | 1,029 |
| Cerus | 637 |
| 4D Molecular Therapeutics | 147 |
| C4 Therapeutics | 145 |
| Aclaris Therapeutics | 91 |
| aTyr Pharma | 59 |
| Candel Therapeutics | 42 |
FHTX News
- 5 days ago - Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities - GlobeNewsWire
- 5 weeks ago - Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update - GlobeNewsWire
- 2 months ago - Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors - GlobeNewsWire
- 2 months ago - Foghorn Therapeutics to Participate in the BMO Oncology Summit - GlobeNewsWire
- 3 months ago - Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer - GlobeNewsWire
- 4 months ago - Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September - GlobeNewsWire
- 4 months ago - Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update - GlobeNewsWire